MAP2K1 and melanoma: Selemetinib, as a selective MEK1 inhibitor for the treatment of solid tumors, could block the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway, thereby regulating cell critical response, and had good activity in pediatric low-grade glioma, non-small cell lung cancer, and melanoma [41].